Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04524897
Other study ID # TIRBESC
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date December 1, 2020
Est. completion date March 2022

Study information

Verified date August 2020
Source Assiut University
Contact ahmed osman, assistant lecturer
Phone 01010168440
Email ahmedzuhry3999@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the efficacy of Intra-lesional triamcinolone injection in the management of refractory benign esophageal Stricture in children.


Description:

Oesophageal stricture is a commonly encountered clinical problem, especially in gastroenterology. It occurs due to narrowing of oesophagus, which results in swallowing difficulty. Oesophageal stricture has two major types: benign and malignant. Malignant type results from carcinoma but benign type has different causes. Amongst benign aetiologies, gastrointestinal reflux disease (GERD), peptic injury, oesophageal webs, radiation damage, caustic swallowing and anastomotic strictures are most common. Corrosive intake is an important public health issue in developed countries and its incidence is still increasing in developing countries. The problem is largely unreported and its exact prevalence cannot be figured out due to the insufficient reporting or personal experience. Corrosives materials can damage the bodies' tissues, as they come in contact with them. They are usually utilised to clean metals. It can cause severe health hazard, if swallowed accidentally or intentionally. Epidemiological studies have documented corrosive intake as the third most common cause of poisoning in adults. The most common symptom of oesophageal stricture is progressive dysphagia to solids followed by inability to tolerate liquids. These strictures are diagnosed most commonly by using barium swallow, endoscopy and biopsy. Endoscopic dilatation is the most applicable method to treat oesophageal strictures, and proton pump inhibitors (PPIs) are also used to inhibit acid production. According to the Kochman criteria, refractory or recurrent strictures are defined as an anatomic restriction because of a cicatricial luminal compromise or fibrosis resulting in clinical symptoms of dysphagia in the absence of endoscopic evidence of inflammation. This may occur as the result of either an inability to successfully remediate the anatomic problem to a diameter of at least 14 mm over five sessions at two-week intervals (refractory); or as a result of an inability to maintain a satisfactory luminal diameter for four weeks once the target diameter of 14 mm has been achieved (recurrent). This definition is not meant to include patients with an inflammatory stricture (which will not resolve until the inflammation subsides), or those with a satisfactory diameter but having dysphagia on the basis of neuromuscular dysfunction (for example those with dysphagia due to postoperative and/or postradiation therapy). Esophageal rehabilitation has been carried out for many years with different techniques, depending on the experience of each physician, esophageal prostheses or splints, dilations with balloons or Savary-Gilliard plugs, Hurst dilators, etc., have been used, but in reality, there is no worldwide standardization for the management of these patients and even less so for the use of certain substances such as triamcinolone acetonide applied intralesionally, or more recently, topical mitomycin C. Triamcinolone acetonide is a synthetic corticosteroid with a preventive effect on collagen synthesis, fibrosis, and chronic cicatrization that has been used for many years, applied in intralesional injection after esophageal dilations for the purpose of delaying cicatrization and thus reducing the number of dilations. Presently, through many studies, it has been concluded that intralesional corticosteroid injections can be added to standard treatment for corrosive oesophageal stricture. International literature exhibited that intralesional steroid injections help in increasing the diameter because of its anti-inflammatory action.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 20
Est. completion date March 2022
Est. primary completion date October 2021
Accepts healthy volunteers No
Gender All
Age group 6 Months to 18 Years
Eligibility Inclusion Criteria: - All patients admitted to Assiut University Children Hospital with: - refractory benign esophageal stricture(inability to successfully remediate the anatomic problem to a diameter of at least 14 mm over five sessions at two-week interval) - inability to maintain a satisfactory luminal diameter for four weeks once the target diameter of 14 mm has been achieved Exclusion Criteria: - Pharyngeal stenosis precluding endoscopic examination and dilatation - tracheo-esophageal fistula, - gastric cicatrization that precluded safe placement of aguidewire - any patient who was unfit for general anesthesia.

Study Design


Intervention

Drug:
Triamcinolone Injection in treatment of refractory benign Esophageal Stricture in children
Triamcinolone Injection in treatment of refractory benign Esophageal Stricture with endoscopic dilatation

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

References & Publications (9)

Berger M, Ure B, Lacher M. Mitomycin C in the therapy of recurrent esophageal strictures: hype or hope? Eur J Pediatr Surg. 2012 Apr;22(2):109-16. doi: 10.1055/s-0032-1311695. Epub 2012 Apr 19. Review. — View Citation

Contini S, Scarpignato C. Caustic injury of the upper gastrointestinal tract: a comprehensive review. World J Gastroenterol. 2013 Jul 7;19(25):3918-30. doi: 10.3748/wjg.v19.i25.3918. Review. — View Citation

Kochman ML, McClave SA, Boyce HW. The refractory and the recurrent esophageal stricture: a definition. Gastrointest Endosc. 2005 Sep;62(3):474-5. — View Citation

Morikawa N, Honna T, Kuroda T, Watanabe K, Tanaka H, Takayasu H, Fujino A, Tanemura H, Matsukubo M. High dose intravenous methylprednisolone resolves esophageal stricture resistant to balloon dilatation with intralesional injection of dexamethasone. Pediatr Surg Int. 2008 Oct;24(10):1161-4. doi: 10.1007/s00383-008-2224-7. — View Citation

Mowry JB, Spyker DA, Cantilena LR Jr, McMillan N, Ford M. 2013 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 31st Annual Report. Clin Toxicol (Phila). 2014 Dec;52(10):1032-283. doi: 10.3109/15563650.2014.987397. — View Citation

Nagaich N, Nijhawan S, Katiyar P, Sharma R, Rathore M. Mitomycin-C: 'a ray of hope' in refractory corrosive esophageal strictures. Dis Esophagus. 2014 Apr;27(3):203-5. doi: 10.1111/dote.12092. Epub 2013 Jun 24. — View Citation

Park KS. Evaluation and management of caustic injuries from ingestion of Acid or alkaline substances. Clin Endosc. 2014 Jul;47(4):301-7. doi: 10.5946/ce.2014.47.4.301. Epub 2014 Jul 28. Review. — View Citation

Poddar U, Thapa BR. Benign esophageal strictures in infants and children: results of Savary-Gilliard bougie dilation in 107 Indian children. Gastrointest Endosc. 2001 Oct;54(4):480-4. — View Citation

Ravich WJ. Endoscopic Management of Benign Esophageal Strictures. Curr Gastroenterol Rep. 2017 Aug 24;19(10):50. doi: 10.1007/s11894-017-0591-8. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary number of patients show improvement in dysphagia scale after five session of triamcinolone injection number of patients show improvement in dysphagia scale after five session of triamcinolone injection 2years
Secondary the number of patients who will show complete relieve of dysphagia after five sessions of triamcinolone injection complete abscence of dysphagia after triamcinolone injection 2years
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04372784 - Cryoablation for Benign Gastrointestinal Anastomotic Strictures N/A
Recruiting NCT05581173 - Self-Assembling Matrix Forming Gel to Prevent Stricture Formation
Terminated NCT04406428 - NKI Therapy Compared to Usual Care of Recurrent Esophagogastric Anastomotic Strictures N/A
Recruiting NCT00551824 - Evaluation of Topical Mitomycin C as Adjuvant Drug to Esophageal Dilation in Children N/A
Completed NCT04284826 - Mitomycin-C Injection Therapy in Refractory Esophageal Stricture N/A
Terminated NCT03898661 - Collagenase Clostridium Histolyticum for Refractory Iatrogenic Esophageal Strictures Early Phase 1
Withdrawn NCT04730076 - Balloon Dilation Methods for Benign Esophageal Stricture N/A
Active, not recruiting NCT03885310 - INGEST I Pilot Study N/A
Completed NCT02069847 - Prospective Evaluation of Budesonide for Prevention of Esophageal Strictures After Endotherapy Phase 2
Completed NCT03039608 - Effect of a Combination of Local Steroid Injection With Oral Steroid Administration for the Prevention on Esophageal Stricture After Endoscopic Submucosal Dissection for Early Esophageal Neoplasm N/A
Terminated NCT02354716 - EndoFLIP Use in Upper GI Tract Stenosis
Recruiting NCT05561114 - Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus Phase 3
Not yet recruiting NCT04221867 - Feasibility and Therapeutic Potential of Free Fat Grafts in the Treatment of Esophageal Strictures (ESOGRAFT) N/A